Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 9 studies | 24% ± 7% | |
enterocyte | 6 studies | 44% ± 10% | |
epithelial cell | 5 studies | 43% ± 24% | |
type II pneumocyte | 4 studies | 24% ± 8% | |
hepatocyte | 3 studies | 53% ± 26% | |
dendritic cell | 3 studies | 28% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 4 studies | 19% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 98% | 1958.23 | 353 / 359 | 97% | 168.90 | 276 / 286 |
intestine | 96% | 7799.51 | 925 / 966 | 98% | 182.55 | 518 / 527 |
bladder | 100% | 3995.48 | 21 / 21 | 87% | 112.56 | 440 / 504 |
liver | 100% | 6095.32 | 226 / 226 | 81% | 65.11 | 329 / 406 |
prostate | 98% | 1571.22 | 241 / 245 | 74% | 44.00 | 370 / 502 |
lung | 100% | 4000.33 | 578 / 578 | 69% | 68.28 | 798 / 1155 |
thymus | 99% | 1204.07 | 646 / 653 | 60% | 18.06 | 365 / 605 |
ovary | 100% | 1383.37 | 180 / 180 | 59% | 20.71 | 254 / 430 |
uterus | 100% | 1378.55 | 170 / 170 | 58% | 31.09 | 266 / 459 |
esophagus | 96% | 823.89 | 1383 / 1445 | 61% | 62.18 | 112 / 183 |
kidney | 99% | 1079.20 | 88 / 89 | 45% | 13.78 | 402 / 901 |
breast | 100% | 2744.06 | 459 / 459 | 38% | 11.18 | 420 / 1118 |
pancreas | 40% | 206.76 | 132 / 328 | 91% | 100.75 | 162 / 178 |
adipose | 100% | 3060.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 54.02 | 29 / 29 |
spleen | 100% | 3239.14 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 74.12 | 1 / 1 |
peripheral blood | 96% | 1996.53 | 896 / 929 | 0% | 0 | 0 / 0 |
heart | 93% | 730.37 | 797 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 75% | 473.29 | 194 / 258 | 4% | 1.19 | 10 / 230 |
brain | 72% | 739.49 | 1896 / 2642 | 3% | 0.71 | 23 / 705 |
blood vessel | 71% | 583.81 | 943 / 1335 | 0% | 0 | 0 / 0 |
skin | 48% | 311.43 | 876 / 1809 | 19% | 6.31 | 91 / 472 |
tonsil | 0% | 0 | 0 / 0 | 44% | 12.54 | 20 / 45 |
muscle | 20% | 98.98 | 162 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.60 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010747 | Biological process | positive regulation of long-chain fatty acid import across plasma membrane |
GO_0001676 | Biological process | long-chain fatty acid metabolic process |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0016020 | Cellular component | membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0004467 | Molecular function | long-chain fatty acid-CoA ligase activity |
GO_0047676 | Molecular function | arachidonate-CoA ligase activity |
GO_0090434 | Molecular function | oleoyl-CoA ligase activity |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | ACSL5 |
Protein name | Long-chain-fatty-acid--CoA ligase 5 (EC 6.2.1.3) (Arachidonate--CoA ligase) (EC 6.2.1.15) (Long-chain acyl-CoA synthetase 5) (LACS 5) Arachidonate--CoA ligase (EC 6.2.1.15) (EC 6.2.1.3) Acyl-CoA synthetase long chain family member 5 Long-chain-fatty-acid--CoA ligase (EC 6.2.1.15) (EC 6.2.1.3) (Acyl-CoA synthetase) (Long-chain acyl-CoA synthetase) |
Synonyms | ACS5 UNQ633/PRO1250 FACL5 |
Description | FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. . FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation . ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells. . |
Accessions | Q9ULC5 ENST00000495539.5 ENST00000433418.6 A0A8C8L3F5 ENST00000354273.5 A0A8C8KCK5 ENST00000356116.6 [Q9ULC5-3] ENST00000354655.9 [Q9ULC5-1] A0A804HIN9 ENST00000393081.6 [Q9ULC5-1] |